In the immunocompromised host, severe infections are difficult to treat with antibiotics. One of the factors that contribute to this lack of success of antibiotic treatment is the failure of the host defense to give adequate support. In this respect it is of great importance to stimulate the nonspecific host defense, in particular, the mononuclear phagocyte system (MPS). This can be effected by the immunomodulating agent muramyl tripeptide phosphatidylethanolamide (MTPPE).
MTPPE is a lipophilic derivative of muramyl dipeptide. Muramyl peptides have various stimulating effects on macrophages (6, 7, 14, 22, 24) and have been proven to be effective in stimulating the nonspecific host defense against several bacterial infections (20, 21) . In a previous study (16) , we investigated the effect of MTPPE in a model of infection induced by intravenous (i.v.) inoculation ofKlebsiella pneumoniae in mice. K pneumoniae is one of the pathogens cultured from samples from infected hospitalized patients and is a serious complication in patients with malignancies (3) . Since these immunocompromised patients are mostly prone to infections during a prolonged period of time, it is expected that repeated administration of immunomodulating agents is needed. Repeated administration of MTPPE has been shown to result in toxic side effects (2, 5, 25) . Encapsulation of MTPPE in liposomes may therefore be of importance, since in this form a reduction in MTPPE toxicity has been demonstrated (5, 25) . In addition, because of liposomal encapsulation, MTPPE is targeted to the cells of the MPS (13, 16) . In the present study, we used an infection model in which K pneumoniae was inoculated intraperitoneally (i.p.), resulting in the appearance of K pneumoniae in the blood at regular intervals, eventually leading to septicemia. This model has a clinical relevance because immunocompromised patients are also prone to the development of septicemia from a local infection. (26) . Then, mice were housed in separate cages, and every day the survival of mice was examined until 21 days after bacterial inoculation. From dead mice only K pneumoniae was recovered from the blood.
In some of the mice, leukopenia was induced by i.p. injections of cyclophosphamide (Sigma Diagnostics, St. Louis, Mo.) at a first dose of 120 mg/kg at 11 days before bacterial inoculation and then at doses of 80 mg/kg every third day thereafter. To quantify the numbers of leukocytes in blood, blood samples (0.8 ml) were taken from the retroorbital plexus and were collected in polypropylene tubes containing 1 mg of dried EDTA (BDH Chemicals Ltd., Poole, England). For total leukocyte counts, blood was diluted 1:10 with Turk solution (0.1% crystal violet in 1% acetic acid), and the number of leukocytes was determined in duplicate in a Burkers hemocytometer. The clearance capacity of these leukopenic mice was compared with that of immunocompetent mice as follows. At different intervals after i.v. inoculation with 104 CFU of K pneumoniae, blood samples (0.8 ml) were taken as described above. Serial 10-fold dilutions were prepared and volumes of 0.2 ml of each dilution were spread onto tryptone soy agar plates (Oxoid Ltd., Basingstoke, England). All plates were incubated overnight at 26°C.
Statistical evaluation of the differences in the decrease in survival with time as well as the eventual percentage of survival between the MTPPE-treated, LE-MTPPE-treated, PBS-treated, and placebo liposome-treated groups of animals was performed by the log rank test (17) . The MannWhitney test was used for evaluation of the differences in the numbers of leukocytes and bacteria between the LE-MTPPE-treated and PBS-treated groups of animals.
After i.p. inoculation of mice with 103 CFU of K pneumoniae, bacteria appeared in the blood and reached levels of 103 to 104 CFU of K pneumoniae per ml of blood within 4 h and 106 CFU per ml blood after 2 days. Eventually, all mice ANTIMICROB. AGENTS CHEMOTHER. an increased survival rate compared with that in PBS-treated leukopenic mice. The numbers of total leukocytes in the blood of LE-MTPPE-treated leukopenic mice did not differ from the numbers in PBS-treated leukopenic mice. They were 670 + 25 and 687 + 26/,u of blood (mean ± standard error of the mean for six mice), respectively. In PBS-treated immunocompetent mice, leukocyte numbers fluctuated around 3,700/,l of blood. The cyclophosphamide treatment in itself did not lead to a decreased capacity of the MPS to clear K pneumoniae from the blood in comparison with the clearance capacity of the MPS of PBS-treated immunocompetent mice ( Table 2) .
Administration of a single dose of MTPPE, LE-MTPPE, muramyl dipeptide (MDP), or other MDP derivatives seemed to be most effective when the dose was given at 24 h before bacterial inoculation (1, 16, 20) . Administration of a single dose of LE-MTPPE after bacterial inoculation did not appear to be effective (16) . The results obtained with repeated administration of MDP derivatives were discrepant (4, 8, 11, 12, 19, 21) . Various microorganisms were used (viruses, bacteria, or parasites), and in most studies only a few treatment schedules were compared. However, a detailed study related to the effects of prophylactic or therapeutic treatment schedules for MDP derivatives has not yet been performed.
Investigations on the efficacy of repeated administration of immunomodulating agents are of clinical relevance since immunocompromised patients are prone to infections during a prolonged period of time. Results of the present study show that the greatest therapeutic effect was obtained when all doses of LE-MTPPE were given prophylactically at an interval of 48 h. This indicates that time is needed for macrophages to become maximally activated. This may be the result of the direct stimulation by LE-MTPPE but also by products released by activated macrophages, such as interleukin-1 or tumor necrosis factor. In addition, more macrophages may be activated during this period of prophylactic administration. In future studies, the activation state and the involvement of cytokines and other cell types in the LE-MTPPE-induced resistance against K pneumoniae infection will be elucidated.
In the present study, we also investigated the effect of stimulating host defenses in leukopenic mice. These mice were immunocompromised as a result of treatment with cyclophosphamide, resulting in a 82% decrease in the numbers of peripheral leukocytes. The effects of repeated prophylactic administration of LE-MTPPE in terms of the increased survival rate and increased percent survival observed in immunocompetent mice could also be found in leukopenic mice. Other investigators (9, 10, 21, 23 ) assessed only the effect of single doses of the MDP derivative administered at 24 h before bacterial inoculation.
Whereas in immunocompetent mice we previously found increased numbers of leukocytes in the blood as a result of LE-MTPPE treatment (16) , the present study demonstrated that, in cyclophosphamide-treated leukopenic mice, the numbers of leukocytes in the blood were not increased after repeated administration of LE-MTPPE. This was due to the cyclophosphamide-induced blockade of the recruitment of leukocytes. It can be concluded that the LE-MTPPE-induced recruitment of leukocytes does not contribute substantially to the therapeutic effect of LE-MTPPE. Activation of tissue macrophages by LE-MTPPE is of major importance in the induced antibacterial resistance in leukopenic mice. In immunocompetent mice, we also found that activation of tissue macrophages is of great importance in the increased resistance against K pneumoniae infections (15). Our results are in agreement with the findings of Nakajima et al. (18) , who indicated that leukocyte numbers in the blood of cyclophosphamide-treated mice were not increased after treatment with the lipophilic MDP-Lys (L18).
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